SEC Form 4 · accession 0001179110-15-009895
Celldex Therapeutics, Inc. · CLDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Avery W Catlin
Officer — Sr. VP & CFO
Period of report
Jun 15, 2015
Accepted (ET)
Jun 16, 2015 · 4:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000744218
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 15, 2015 | M | 25,000 | $8.52 | A | 49,609 | D | |
| Common StockF3 | Jun 15, 2015 | S | 25,000 | $24.5901 | D | 24,609 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF2,F1 | $8.52 | Jun 15, 2015 | M | 25,000 | D | Jan 6, 2010 | Jan 6, 2019 | Common Stock | 25,000 | 0 | D |
Explanation of responses
- F1The sale reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12,2015. The options exercised and sold by the Reporting Person were due to expire January 6,2019.
- F225% of the shares vested on January 6, 2010 and the remainder vested quarterly (in equal amounts) over the subsequent 12 quarters.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.35 to $25.23, inclusive. The Reporting Person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.